FHI Clinical goes where our expertise is needed. Whether it requires working from a state-of-the-art facility or in a low-tech, rural setting, we provide services tailored to meet your study needs, from protocol design and site assessments to trial planning, implementation and management.
FHI Clinical has long-standing relationships, a local team and broad expertise in sub-Saharan Africa. We're ready to help you confidently expand your research across the region, finding the best-fit countries and populations for your target indication and study type.
For more than 10 years, the FHI Clinical project team has partnered with companies developing and deploying vaccines, treatments and preventive devices for malaria in 35 countries worldwide.
For nearly 20 years, the FHI Clinical project team has partnered with companies developing and deploying vaccines, treatments and diagnostic tests for multiple oncology indications.
Following a trip to the PREVAIL network of sites in Liberia, we asked FHI Clinical team members for their feedback on the types of training, knowledge and skills that are important for the site staff to encompass. Watch this video to learn what qualities the experts evaluated during their trip.
Our site managers partner with study sites to ensure their success throughout the length of the project. This can include training and re-training for procedures, processes, protocol, ICH GCP, data management, informed consent and more.
The Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) network was established through a partnership between local Liberian and international partners, including the U.S. National Institutes of Health, World Health Organization and FHI Clinical, to provide sustainable research infrastructure to address diseases of public health importance.
Since 1976, Ebola virus disease outbreaks have primarily occurred in eleven countries: Democratic Republic of the Congo, Gabon, Guinea, Liberia, Mali, Nigeria, Republic of Congo, Sierra Leone, Sudan and Uganda. Although it is generally rare, it is often fatal, with death rates ranging from 25 to 90% in past outbreaks (average case fatality rate, 50%). No treatment or vaccine is currently approved, but there are several promising vaccines and treatments under development.
In a study conducted at 17 sites spanning nine countries in a Zika endemic region of the Americas and Caribbean, timely staffing of contract research associates (CRAs) was enabled by the project team’s network of bilingual resources and knowledge of local hiring practices.
To equip Liberia with the ability to respond to ongoing health issues and potential outbreaks, a US government contract provided funding to train local leaders in Liberia’s clinical research infrastructure network. The training aimed to build a solid foundation to conduct international quality clinical research.
FHI Clinical Headquarters
359 Blackwell Street, Suite 200
Durham, NC 27701 USA